Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability.” The feature highlights how breakthroughs in nanocarrier-based delivery are reshaping cancer therapy by enhancing efficacy and reducing toxicity. Oncotelic’s proprietary Deciparticle(TM) platform is spotlighted for its potential to improve the bioavailability and therapeutic index of oncology drugs, advancing the broader shift toward precision nanomedicine.
The editorial underscores the transformative impact of nanotechnology on oncology drug development. Traditional chemotherapy often suffers from poor bioavailability and systemic toxicity, limiting its effectiveness. Nanocarrier systems, such as Oncotelic’s Deciparticle platform, can encapsulate drugs to protect them from degradation, target them to tumor sites, and release them in a controlled manner. This approach not only enhances drug accumulation at the tumor but also reduces off-target effects, potentially leading to better patient outcomes and fewer side effects.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products for high-unmet-need cancers and rare pediatric indications. The company’s pipeline includes late-stage therapeutic candidates driven by its proprietary technology platforms. In addition to its directly owned programs, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. The company also engages in licensing and codevelopment agreements through joint ventures, such as its 45% ownership of GMP Bio, which is advancing its own pipeline of drug candidates that complement Oncotelic’s strategic position in oncology and rare disease therapeutics.
The full press release regarding Oncotelic’s inclusion in the editorial can be accessed at https://nnw.fm/F5U3f. For the latest news and updates on Oncotelic Therapeutics, visit the company’s newsroom at https://nnw.fm/OTLC.
NetworkNewsWire is a specialized communications platform focusing on financial news and content distribution for private and public companies and the investment community. It is one of over 70 brands within the Dynamic Brand Portfolio @IBN that provides access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, enhanced press release services, social media distribution via IBN to millions of followers, and tailored corporate communications solutions. With broad reach and a seasoned team of journalists and writers, NNW is uniquely positioned to serve companies that want to reach a wide audience of investors, consumers, journalists, and the general public.
